UroGen Pharma (URGN) Cash from Operations Growth (3y) (2021 - 2026)
UroGen Pharma (URGN) Cash from Operations Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | UroGen Pharma | 2.05 Bn | 1.91 Bn | 46.82 Mn | -20.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.64% |
| Dec 31, 2025 | -20.78% |
| Sep 30, 2025 | -33.89% |
| Jun 30, 2025 | -18.06% |
| Mar 31, 2025 | -20.54% |
| Dec 31, 2024 | 12.12% |
| Sep 30, 2024 | -14.40% |
| Jun 30, 2024 | -7.82% |
| Mar 31, 2024 | -5.02% |
| Dec 31, 2023 | 15.11% |
| Sep 30, 2023 | 11.64% |
| Jun 30, 2023 | 5.38% |
| Mar 31, 2023 | 10.20% |
| Dec 31, 2022 | 5.77% |
| Sep 30, 2022 | -12.02% |
| Jun 30, 2022 | -18.47% |
| Mar 31, 2022 | -10.19% |
| Dec 31, 2021 | -24.97% |
| Sep 30, 2021 | -25.81% |
| Jun 30, 2021 | -32.48% |